Coronary CT Angiogram: Sex- and Cycle-Related Differences, Normal Ranges, and Optimal Targets

Updated Jul 14, 2025

Image: HealthRX.com clinical image

A coronary CT angiogram (CCTA) is a contrast-enhanced CT scan of the heart's arteries, read using the CAD-RADS scoring system and, separately, a coronary artery calcium (Agatston) score. It is not the same test as a plain calcium-score-only CT, a cardiac MRI, or an invasive catheter angiogram, though it is often confused with all three. Biological sex and hormonal status change what a "normal" CCTA looks like enough that the same numeric score can mean different things in a man and a woman of the same age, and in the same woman before and after menopause.

The useful question is not whether a CCTA result is "normal" in the abstract, but normal for whom. A calcium score, stenosis grade, or plaque description that is reassuring in a 55-year-old man may sit at a meaningfully worse percentile in a woman of the same age, because women carry a larger share of their atherosclerotic burden as non-calcified plaque that standard calcium scoring underrepresents. This is established by CAD-RADS 2.0 reporting conventions and by observational registry data on sex differences in plaque phenotype; it is not a fringe claim, but it is frequently omitted from a plain read of a CCTA report.

At a glance

Test / Coronary CT angiogram (CCTA)
Category / Cardiovascular imaging
Primary metrics / Percent luminal stenosis (CAD-RADS 0-5), plaque volume, plaque composition (calcified, non-calcified, mixed)
Optimal result / CAD-RADS 0 with no plaque ("P") modifier and an Agatston calcium score of 0
Sex difference (established) / Women tend to have smaller coronary artery diameters and a higher proportion of non-obstructive, diffuse plaque relative to focal obstructive stenosis, compared with men at similar ages
Hormone relevance (plausible, mechanistically supported, not fully quantified) / Higher estrogen exposure is associated with less calcified and more non-calcified/lipid-rich plaque; the reverse pattern appears after estrogen withdrawal at menopause
Radiation dose / Modern CCTA with prospective ECG gating is typically in the low single-digit millisievert range, lower than many general chest CT protocols
Fasting / Typically 4 hours; beta-blocker pre-medication is commonly used if resting heart rate exceeds roughly 65 bpm
Contrast / Iodinated contrast is required; reduced kidney function changes the prep and hydration protocol

What CAD-RADS actually grades

The Society of Cardiovascular Computed Tomography maintains CAD-RADS as the standard coronary CT reporting scale, most recently updated as CAD-RADS 2.0. The categories run from CAD-RADS 0 (no plaque, 0% stenosis) through CAD-RADS 5 (total occlusion), with intermediate grades corresponding to increasing percent stenosis. A "P" modifier is appended when any plaque is visible even at 0% stenosis, and this modifier changes prognosis: a clean lumen with visible plaque is not the same finding as a clean lumen with none.

This matters directly for the sex question. Because women more often carry plaque burden as diffuse, non-calcified disease rather than focal calcified lesions, a stenosis-only read (ignoring the P modifier and plaque composition) is more likely to under-communicate risk in a woman's report than in a man's.

How biological sex changes what a CCTA shows

Two anatomic and biologic differences are well established and matter for interpretation.

Vessel caliber. Women's coronary arteries tend to have smaller luminal diameters than men's at a comparable body size. This has a direct measurement consequence: the same absolute plaque volume narrows a smaller vessel by a larger percentage, so percent-stenosis grading can look more severe in a woman for an equivalent plaque burden, and image resolution has less margin for error.

Plaque distribution. Registry data on patients referred for CCTA consistently describe a pattern in which women present with more non-obstructive disease and men present with more focal obstructive disease at similar ages, even though total cardiovascular risk in women with non-obstructive plaque is not negligible. This general pattern is supported by cardiology registry literature; the specific numeric comparisons that circulate about exact percentages and cohort sizes for this pattern should be checked against the primary registry publication before being quoted precisely, since we could not verify a specific source for those exact figures in preparing this draft.

MINOCA. Myocardial infarction with non-obstructive coronary arteries is a recognized clinical phenotype, disproportionately represented in women, especially those under 55. A CCTA in this setting often shows either angiographically normal-appearing coronary arteries (raising the possibility of microvascular dysfunction or spontaneous coronary artery dissection) or diffuse non-calcified plaque without any single stenosis severe enough to be labeled "obstructive." A CCTA read as reassuring by stenosis criteria alone can still miss the mechanism behind a woman's chest pain or a prior troponin-positive event, which is why guideline statements on myocardial infarction in women emphasize that normal large-vessel anatomy does not rule out ischemia.

Estrogen, the menstrual cycle, and menopause: what is established versus what is plausible

Established: Estrogen has recognized vascular biology, including effects on endothelial nitric oxide production, LDL oxidation, and HDL-mediated cholesterol transport. The menopausal transition is associated with accelerated increases in coronary calcium in longitudinal cohort studies of women followed through this period.

Plausible but not fully quantified on CCTA specifically: That higher circulating estradiol correlates with a shift toward less-calcified, more lipid-rich plaque, and that specific estradiol thresholds (for example, a particular pg/mL cutoff) predict a specific fold-change in plaque odds. Cohort studies describing quartile-based associations between estradiol level and plaque presence exist in the literature, but the precise numbers attributed to any single study should be verified against the original paper before being used as a clinical cutoff. We are not able to confirm the exact figures cited in earlier drafts of this material against a specific verified source, so they have been removed rather than repeated as fact.

Not established: A validated, hormone-adjusted CCTA reference range that clinicians currently use in practice. Sex-specific calcium score percentiles (such as the widely used MESA-derived tables) exist and are guideline-referenced, but a further adjustment layer for estradiol level, cycle phase, or progestogen type is not part of standard clinical reporting today, even though the underlying biology is a reasonable hypothesis.

Menstrual cycle and scan quality: The menstrual cycle is not expected to change plaque volume within a single cycle. There is physiologic literature describing cycle-related differences in heart rate and vascular reactivity, with somewhat lower resting heart rate in the follicular phase for some women. Because CCTA image quality depends on achieving a resting heart rate at or below roughly 65 bpm, timing an elective scan in the follicular phase is a reasonable scheduling consideration for some patients, not a clinical requirement, and should not delay urgent or symptom-driven imaging.

Hormone therapy: Menopausal hormone therapy's relationship to vascular outcomes is timing-dependent, a pattern often called the "timing hypothesis" and reflected in current menopause society guidance: earlier initiation relative to the final menstrual period is associated with more favorable vascular findings than initiation many years after menopause, in trials measuring carotid intima-media thickness rather than CCTA plaque directly. Progestogen choice may modify these effects, with micronized progesterone generally regarded as more vascular-neutral than some synthetic progestins, but CCTA-specific outcome data stratified by progestogen type are limited. This is an area where site judgment and shared decision-making with a patient's own hormone therapy prescriber matter more than a single imaging number.

Testosterone: opposite directions in women and men

In women, testosterone's relationship to plaque appears non-linear, with some cohort data suggesting that androgen excess, as seen in polycystic ovary syndrome, may be associated with greater plaque accumulation independent of estrogen status, and with PCOS associated with more non-calcified plaque at younger ages than matched controls. Because that plaque tends to be non-calcified, a reassuring calcium score of zero does not exclude meaningful plaque burden in a woman with PCOS, and full plaque characterization on the CCTA report deserves explicit attention rather than a glance at the calcium number alone.

In men, low testosterone is associated in observational studies with higher calcium scores and greater total plaque volume, the opposite direction from what intuition might suggest. Testosterone replacement therapy in hypogonadal men did not show excess cardiovascular events compared with placebo in a large randomized cardiovascular safety trial, though that trial was designed to detect major adverse cardiac events, not CCTA-specific plaque progression, so it does not directly answer whether TRT changes plaque composition over years of use. Men who use aromatase inhibitors alongside testosterone therapy suppress conversion to estradiol, and since estradiol contributes to vascular protection in men through similar pathways as in women, this combination is mechanistically plausible as a modifier of vascular benefit, though CCTA data testing this specific question directly are limited.

Radiation and contrast: sex-specific safety notes

Modern prospectively ECG-gated CCTA delivers a radiation dose in the low single-digit millisievert range, generally lower than older retrospective-gating protocols or a standard chest CT. Because breast tissue overlies the imaging field, women carry a somewhat higher lifetime radiation risk per unit dose than men for the same scan; the absolute added risk from a single modern low-dose scan is small but not zero, and bismuth breast shields are used at many centers to reduce surface dose without degrading image quality.

Iodinated contrast carries a small risk of contrast-associated kidney injury. Reduced kidney function changes preparation, including IV hydration protocols and temporary interruption of metformin after contrast in patients with lower eGFR. A urine pregnancy test on the day of the scan is standard practice for women of reproductive potential at accredited centers, and CCTA is generally deferred in favor of non-radiation alternatives such as echocardiography and stress testing if pregnancy cannot be excluded.

Reading the report: what each number means in context

Calcium (Agatston) score. Sex- and age-specific percentile tables (commonly derived from the MESA cohort) are the accepted way to interpret a raw calcium score; a given score sits at a different percentile in a woman than in a man of the same age, and clinicians should reference the percentile, not just the raw number, when discussing risk.

Plaque characterization. Calcified plaque is generally considered lower risk for near-term rupture but is associated with long-term stenosis progression. Non-calcified and low-attenuation plaque is the phenotype most likely to be underrepresented by calcium scoring alone, and this matters more in women and in anyone with a low-estrogen or hyperandrogenic profile.

Stenosis grade in context. The same CAD-RADS grade may carry different clinical weight depending on hormonal context, for example in a postmenopausal woman recently off long-term estrogen therapy versus a premenopausal woman with an intact estrogen environment. This is a reasonable clinical judgment supported by the broader biology above, not a validated scoring adjustment.

Pericoronary fat attenuation. An emerging, not yet universally reported, CT-derived marker of coronary inflammation. It is a promising research and early-clinical tool; whether its normal range or prognostic cutoffs differ meaningfully by sex or menopausal status is not yet firmly established and needs confirmation from larger, sex-stratified studies before being treated as validated.

Decision framework: applying sex and hormone context to a CCTA result

This framework is a structured way to think through a CCTA result alongside hormonal context. It does not replace individualized medical advice, and it does not set a dose, threshold, or diagnosis for any specific person.

Reader scenario	What "normal" likely understates	What to ask your clinician	When to escalate urgently
Premenopausal woman, CAD-RADS 0, calcium score 0	Little; this is genuinely reassuring, but note that a future low-estrogen state (menopause, oophorectomy) can change the trajectory	Whether a repeat scan interval makes sense given family history	Chest pain, especially with exertion, regardless of prior scan result
Recently postmenopausal woman, low-to-moderate calcium score	Non-calcified plaque may be under-captured by the calcium number alone; the recent hormonal transition is associated with faster plaque accumulation in cohort studies	Whether full plaque characterization (not just the calcium score) was reviewed, and whether statin therapy timing should be reconsidered given the transition	New or worsening chest pain, shortness of breath, or a prior troponin-positive event with a "normal" scan
Woman with PCOS or hyperandrogenism, calcium score 0	Non-calcified plaque is disproportionately represented in this group and calcium scoring alone can miss it	Whether the radiologist explicitly commented on non-calcified plaque, not just stenosis grade	Any exertional or atypical chest symptoms, given the higher rate of non-obstructive plaque in this group
Man with low testosterone and an elevated calcium score	The association between low testosterone and higher plaque burden is observational, not proof of cause; do not assume TRT will lower the score	Whether hypogonadism workup and cardiovascular risk management should proceed in parallel, not sequentially	Any chest pain, regardless of testosterone status
Man on TRT with an aromatase inhibitor	Long-term CCTA plaque data for this combination are limited; short-term cardiac event data (TRAVERSE) do not directly answer the plaque-progression question	Whether estradiol levels are being monitored alongside testosterone, and why the aromatase inhibitor is being used	Any new cardiac symptoms; do not rely on a prior clean scan as ongoing reassurance if therapy has changed since then
Anyone with chest pain and a "clean" CCTA	A normal large-vessel angiogram does not rule out microvascular dysfunction, vasospasm, or dissection, especially in women under 55	Whether further evaluation for MINOCA or microvascular disease is warranted given the symptom picture	Ongoing or recurrent chest pain after a "normal" scan is not self-reassuring and needs clinical follow-up, not just a repeat scan

The exceptions worth remembering: none of the hormone-related associations above have been turned into a validated adjustment factor for CAD-RADS or calcium-score interpretation. They are reasons to look more carefully at plaque composition and clinical context, not reasons to override a radiologist's formal read with a self-calculated risk adjustment.

What preparation involves

Standard preparation applies across sexes: a several-hour fast, avoiding caffeine for roughly 12 hours before the scan because caffeine can blunt beta-blocker effect, and avoiding PDE5 inhibitors (erectile dysfunction medications) for about 24 hours before the scan because of nitrate interaction risk if nitroglycerin is needed during the study. Centers commonly require a same-day urine pregnancy test for women of reproductive potential, and patients on hormone therapy, oral contraceptives, or TRT should make sure the ordering clinician and the imaging center know their current regimen, since it may inform how the images are interpreted even though it typically does not change scan-day preparation itself.

Evidence boundary

Established: CAD-RADS grading conventions, the existence of sex-based differences in coronary vessel size and plaque distribution, the association between the menopausal transition and accelerated calcium accumulation in longitudinal cohorts, and the recognition of MINOCA as a distinct phenotype more common in younger women.

Plausible but not fully proven at the level of a validated clinical adjustment: specific estradiol thresholds predicting specific fold-changes in plaque odds, a hormone-adjusted CCTA reference range, and the exact quantitative effect of progestogen type or aromatase inhibition on coronary plaque as seen on CT.

Not established: any universal recommendation to change CCTA scheduling around a menstrual cycle for clinical (rather than scan-quality) reasons, or a validated re-scan interval after a clean baseline result; current practice on repeat imaging intervals is institutional convention rather than randomized-trial-derived guidance.

If you have chest pain, shortness of breath, or other symptoms concerning for a heart attack, seek emergency care immediately rather than waiting for or relying on a scheduled or prior CCTA result.

Frequently asked questions

What counts as an optimal coronary CT angiogram result?

An optimal result is CAD-RADS 0 with no plaque modifier and an Agatston calcium score of 0, ideally with no low-attenuation non-calcified plaque described. A raw score should be interpreted against age- and sex-specific percentile tables rather than a single universal number, since the same score sits at a different percentile for a man and a woman of the same age.

Does the menstrual cycle affect coronary CT angiogram results?

The menstrual cycle is not expected to change plaque volume within a single cycle. Some women have modestly lower resting heart rate in the follicular phase, which can help meet the heart-rate target needed for a high-quality scan. This is a scheduling consideration, not a reason to delay clinically indicated imaging.

Why do some women with chest pain have a normal-looking CCTA?

Women more often have microvascular coronary dysfunction or diffuse non-obstructive plaque rather than a single severe blockage. A CCTA can look reassuring by stenosis grading alone while still missing meaningful non-calcified plaque burden or a microvascular cause of symptoms, which is why normal large-vessel anatomy does not rule out cardiac ischemia.

Does menopause change what a normal CCTA looks like?

Longitudinal cohort studies describe faster coronary calcium accumulation around the final menstrual period than in the years before it. Postmenopausal women with low estrogen tend to show plaque patterns that look more like age-matched men than like premenopausal women, which is a reason to look at plaque composition, not just the calcium score, when interpreting a postmenopausal woman's scan.

Does hormone therapy affect coronary calcium or plaque on CT?

Trial data measuring carotid artery thickness, not CCTA plaque directly, suggest a timing-dependent effect: starting estrogen-based therapy closer to menopause is associated with more favorable vascular findings than starting many years after menopause. Direct CCTA-specific randomized data on hormone therapy and plaque progression are limited, and this should be discussed with the clinician managing hormone therapy rather than decided from imaging alone.

Does low testosterone in men raise coronary calcium scores?

Observational studies associate lower testosterone with higher coronary calcium and greater plaque burden in men, though association does not prove that testosterone replacement will lower an existing score. A large randomized cardiovascular safety trial of testosterone therapy did not show excess cardiac events, but it was not designed to measure changes in coronary plaque on CT.

Can PCOS increase coronary plaque that shows up on CCTA?

Cohort studies describe more non-calcified plaque in women with PCOS at younger ages compared with matched controls, even after accounting for weight and insulin resistance. Because this plaque tends to be non-calcified, a calcium score of zero does not exclude meaningful plaque burden in this group, and the full plaque characterization on the report should be reviewed.

How often should a CCTA be repeated?

There is no randomized trial establishing a universal repeat interval. Practice varies by institution: a clean baseline scan is sometimes followed by re-imaging around five years if new risk factors develop, and scans showing mild disease on medical therapy are sometimes repeated sooner. This is a matter of clinical judgment and local protocol rather than settled guidance.

References for editorial verification

This article references CAD-RADS guidelines established by the Society of Cardiovascular Computed Tomography, published registry analyses examining sex-based differences in coronary atherosclerosis, observational studies tracking coronary calcification through menopause, and clinical trial results evaluating hormone therapy effects on carotid disease and testosterone replacement safety. A resource on reproductive health physiology appears in the references below. During revision, certain numeric citations from earlier drafts could not be confirmed against their original sources and were accordingly removed or restated using cautious language. Prior to final publication, an editor with access to primary sources should verify citations supporting specific quantitative values (coronary calcium percentiles, estrogen levels, participant numbers, and effect sizes) or confirm that the current cautious phrasing adequately represents the evidence.

General reproductive health background: https://www.cdc.gov/reproductivehealth/index.html